Companies Profiled in U.S. Compounding Pharmacies Market are B. Braun Medical, Cantrell Drug Company, Inc., Clinigen Group

Growing demand for compounded medicine will serve to be a key factor that will drive the U.S. compounding pharmacies market growth. Convenience and benefits offered by compounding pharmacies such as ability to compound medications that are not produced commercially or formulate liquid doses for patient with difficulty in swallowing pills will increase the adoption of compounded drugs. Customized medication prepared by compounding pharmacies can thus provide better health outcomes for majority of patients, thereby augmenting the compounding pharmacies industry size.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2961

Oral segment dominated the U.S. compounding pharmacies product segment with more than USD 1.4 billion revenue in 2017. The high market value is attributable to increasing demand for oral medication in the treatment of pain management. Furthermore, growing preference for liquid oral medication over other dosage forms due to associated convenience and ease of administration, especially among the pediatric and geriatric patient population will foster segmental growth.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• Braun Medical
• Fresenius Kabi
• Fagron
• Cantrell Drug Company, Inc.
• Clinigen Group
• Dougherty's Pharmacy, Inc.
• McKesson Corporation
• Nephron Pharmaceuticals
• Pentec Health
• PharMEDium Services
• Wells Pharmacy Network

Parenteral product segment held significant revenue share in 2017 and is estimated to witness a considerable CAGR of 5.3% owing to benefits offered by parenteral medication including rapid onset of action and quick localized drug delivery. Moreover, growing demand for compounded parenteral nutrition (PN) such as two-in-one compounded PN, two premixed chamber PN and three premixed chamber PN will spur the market size over the forecast period. However, requirement of skilled persons for administration and stringent regulations may limit the segmental growth.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2961

Pharmaceutical ingredient alteration (PIA) segment accounted for USD 1.7 billion in 2017 and is estimated to show robust growth during the forthcoming years. Individuals allergic to a common preservative or additive require hypoallergenic versions of drugs that are commercially unavailable. This will increase the demand for drugs compounded by altering certain pharmaceutical ingredients thereby propelling the business growth.

U.S. compounding pharmacies market, by pharmacy type
• 503A compounding pharmacy
• 503B compounding pharmacy

U.S. compounding pharmacies market, by sterility
• Sterile
• Non-sterile

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.